CLRB News and Press, Cellectar Biosciences Inc. From 03/19/19

FLORHAM PARK, N.J., March 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Ad...

Cellectar Biosciences (NASDAQ: CLRB ): FY GAAP EPS of -$5.23 misses by $0.70. Cash, cash equivalents and restricted cash of $13.3M Press Release More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

FLORHAM PARK, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ...

Thinly traded nano cap Cellectar Biosciences ( CLRB +7.2% ) is up on more than a 7x surge in volume, albeit on turnover of only 424K shares, in response to new data from a Phase 2 clinical trial, CLOVER-1 , evaluating lead candidate CLR 131 in patients with treatment-resistant B-cell bl...

Company’s lead product candidate previously demonstrated positive top-line results from the diffuse large B-cell lymphoma cohort of this study Dosing in multiple tumor types is ongoing; Cellectar intends to report additional data this year FLORHAM PARK, N.J., Feb. 25, 2019 (...

FLORHAM PARK, N.J., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, preside...

FLORHAM PARK, N.J., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, presiden...

FLORHAM PARK, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced median overall survival (mOS) in Cohorts 1...

MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso, president and chief e...

NEW YORK, NY / ACCESSWIRE / September 27, 2018 / U.S. markets fell sharply Wednesday after the Federal Reserve raised interest rates and indicated another increase would be coming in December. The Dow Jones Industrial Average dropped 0.4 percent to close at 26,385.28, while the S&P 500 ...